Kingfisher Capital LLC Sells 112 Shares of Illumina, Inc. (ILMN)

Kingfisher Capital LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,426 shares of the life sciences company’s stock after selling 112 shares during the period. Illumina comprises approximately 1.1% of Kingfisher Capital LLC’s portfolio, making the stock its 29th largest position. Kingfisher Capital LLC’s holdings in Illumina were worth $1,636,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after buying an additional 255,498 shares during the period. Capital World Investors boosted its position in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after buying an additional 410,000 shares during the period. TIAA CREF Investment Management LLC boosted its position in Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after buying an additional 527,548 shares during the period. Geode Capital Management LLC boosted its position in Illumina by 8.0% during the 1st quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after buying an additional 107,941 shares during the period. Finally, Winslow Capital Management LLC acquired a new stake in Illumina during the 2nd quarter worth approximately $211,584,000. Institutional investors and hedge funds own 93.32% of the company’s stock.

In related news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $176.43, for a total value of $3,528,600.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at $94,244,671.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 22,540 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total value of $4,400,033.40. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 178,516 shares of company stock valued at $34,995,591. Insiders own 1.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/12/kingfisher-capital-llc-sells-112-shares-of-illumina-inc-ilmn.html.

Illumina, Inc. (NASDAQ:ILMN) traded up 0.85% during mid-day trading on Thursday, hitting $208.44. 406,780 shares of the stock traded hands. The firm has a market capitalization of $30.43 billion, a P/E ratio of 41.82 and a beta of 0.76. The company has a 50-day moving average of $203.70 and a 200 day moving average of $185.30. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.34.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. The firm had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.86 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.

Several equities research analysts recently commented on ILMN shares. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price on the stock. in a research report on Wednesday, June 21st. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price on the stock in a research report on Thursday, July 27th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and lifted their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Argus lifted their target price on shares of Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price on the stock in a research report on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. Illumina currently has an average rating of “Hold” and a consensus price target of $187.85.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit